Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Growth Hormone-Secreting Pituitary Adenoma × Clear all
NCT00006368 2013-05-01

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Novartis

Phase 1 Completed
60 enrolled
BreastCNSDermatologicEndocrineLymphoidOther hematologic neoplasmSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Craniopharyngioma, Vipoma, Ependymoma, Glioblastoma, Glucagonoma, Hodgkin Disease, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Pituitary Neoplasms, Somatostatinoma, Gastrinoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Carcinoma, Islet Cell, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Growth Hormone-Secreting Pituitary Adenoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Small Cell Lung Carcinoma